ponatinib
Showing 1 - 25 of 77
Ponatinib in CML Patients in Chronic Phase
Recruiting
- Chronic Myeloid Leukemia, Chronic Phase
- Therapeutic drug monitoring
- Molecular Response
-
Cagliari, Italy
- +4 more
Nov 3, 2023
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Trial in Frankfurt (Imatinib, Ponatinib, Blinatumomab)
Recruiting
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Imatinib
- +3 more
-
Frankfurt, GermanyDepartment of Medicine, Hematology and Oncology, Goethe Universi
Sep 24, 2023
Chronic Myeloid Leukemia Any Phase Treated With Ponatinib at Any
Active, not recruiting
- Chronic Myeloid Leukemia, Chronic Phase
-
Jena, GermanyUniversity Hospital Jena
Jan 17, 2023
Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and
Completed
- Leukemia
- No Intervention
-
Cambridge, MassachusettsTakeda
Feb 28, 2023
Acute Lymphoblastic Leukemia, Leukemia Trial in Houston (Ponatinib, Venetoclax, Mini-hyper CVD)
Recruiting
- Acute Lymphoblastic Leukemia
- Leukemia
- Ponatinib
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Aug 23, 2022
Acute Lymphoblastic Leukemia, Adult, Ph+ ALL, Newly Diagnosed Trial in Czechia (Ponatinib 15 MG Oral Tablet)
Active, not recruiting
- Acute Lymphoblastic Leukemia, Adult
- +2 more
- Ponatinib 15 MG Oral Tablet
-
Brno, Czechia
- +6 more
Nov 30, 2022
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous
Recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +6 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 31, 2022
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic
Recruiting
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +2 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jun 15, 2022
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein
Recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +7 more
- Blinatumomab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
Leukemia, Myeloid, Chronic-Phase Trial in Germany (Ponatinib)
Active, not recruiting
- Leukemia, Myeloid, Chronic-Phase
- Ponatinib
-
Halle (Saale), Saxony-Anhalt, Germany
- +9 more
Sep 9, 2022
Chronic Phase Chronic Myeloid Leukemia Trial in Bruxelles (Ponatinib 30 mg QD, Ponatinib 15 mg QD, Nilotinib 400 mg BID)
Terminated
- Chronic Phase Chronic Myeloid Leukemia
- Ponatinib 30 mg QD
- +2 more
-
Bruxelles, BelgiumCliniques Universitaire Saint-Luc (Site 058)
Oct 28, 2021
Acute Lymphoblastic Leukemia Trial in Ann Arbor (Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy)
Recruiting
- Acute Lymphoblastic Leukemia
- Dasatinib
- +3 more
-
Ann Arbor, MichiganUniversity of Michigan Rogel Cancer Center
Nov 28, 2022
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic
Active, not recruiting
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +6 more
- Dexamethasone
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 2, 2022
CML Patients in the National Compassionate Program
Terminated
- Chronic Myeloid Leukemia
- Philadelphia Positive
- Ponatinib
-
Bari, Italy
- +9 more
Oct 24, 2022
Non Small Cell Lung Cancer, KRAS Gene Mutation Trial in United States (Trametinib 0.5 mg, Trametinib 1 MG, Trametinib 1.5 MG)
Completed
- Non Small Cell Lung Cancer
- KRAS Gene Mutation
- Trametinib 0.5 mg
- +5 more
-
Basking Ridge, New Jersey
- +6 more
Feb 7, 2022
Medullary Thyroid Cancer Trial (Ponatinib)
Withdrawn
- Medullary Thyroid Cancer
- Ponatinib
- (no location specified)
Oct 6, 2021
Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer Trial in Aurora
Completed
- Adenocarcinoma of the Lung
- +7 more
- Ponatinib
-
Aurora, ColoradoUniversity of Colorado Cancer Center
Jan 19, 2022
Chronic Myeloid Leukemia, Chronic Phase Trial in Spain (Ponatinib 15 MG, Acetylsalicylic acid 100 MG)
Recruiting
- Chronic Myeloid Leukemia, Chronic Phase
- Ponatinib 15 MG
- Acetylsalicylic acid 100 MG
-
L'Hospitalet De Llobregat, Barcelona, Spain
- +12 more
Feb 8, 2022
Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia Trial in Worldwide
Recruiting
- Acute Myeloid Leukemia
- +8 more
- Ponatinib
-
Ghent, Belgium
- +28 more
Nov 11, 2022
Leukemia, Myeloid, Acute Trial in France (Ponatinib 30 MG)
Recruiting
- Leukemia, Myeloid, Acute
- Ponatinib 30 MG
-
Angers, France
- +13 more
Aug 4, 2021
Philadelphia Chromosome Positive CML, BCR-ABL Positive Chronic Myelogenous Leukemia Trial in France (Ponatinib, Imatinib)
Recruiting
- Philadelphia Chromosome Positive CML
- BCR-ABL Positive Chronic Myelogenous Leukemia
- Ponatinib
- Imatinib
-
Amiens, France
- +27 more
Dec 9, 2021
Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL Trial in Italy (Ponatinib
Recruiting
- Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
- +2 more
- Ponatinib + Blinatumomab
- Chemotherapy + Imatinib
-
Ascoli Piceno, Italy
- +14 more
Jan 3, 2022
Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse Trial in Italy (Ponatinib)
Recruiting
- Philadelphia-Positive ALL
- Acute Lymphoblastic Leukemia, in Relapse
- Ponatinib
-
Ancona, Italy
- +21 more
Jan 3, 2022